Researchers at Invicro UK (formerly Imanova) Limited have produced and tested a promising new imaging biomarker which may help to accelerate drug development for CNS disorders whilst further elucidating the function of the phosphodiesterase 10A (PDE10A) enzyme – a key target in CNS disorders which holds the interest of the pharmaceutical industry and academics alike.
The positron emission tomography (PET) imaging biomarker, 11C-IMA-107, will assist in research to distinguish the differences in how PDE10A is expressed in CNS disorders and also boost understanding of pharmacological endpoints to. It is a carbon-11 labelled molecule which binds the PDE10A enzyme, allowing visualisation and quantification of the levels of the protein in the brain. This can provide valuable insight into PDE10A levels in disease and in response to drugs.
Invicro UK researchers demonstrated that [11C]IMA107 could provide information to further elucidate the PDE10A function, characterise PDE10A expression in disease populations, and also help understanding pharmacological endpoints and therefore accelerate drug development.